EUVIMEDEUVIMED entdecken
KorrekturLeitlinieOpen Access

Correction: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis

Elisabeth Schnoy, Axel Dignass, Matthew Gaskins, Torsten Kucharzik

Zeitschrift für Gastroenterologie · 01.10.2025 · 63 (10) · e668-e669

DOI: 10.1055/a-2832-4215 ↗

Kurz gefasst

Korrektur in der Zeitschrift Zeitschrift für Gastroenterologie, erschienen am 01.10.2025. Verfasst von Elisabeth Schnoy und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine III, University Hospital Augsburg, Augsburg, Germany. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Correction to: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis Z Gastroenterol 2025; 63(10): 1053-1067 DOI: 10.1055/a-2596-8934 10.1055/a-2596-8934 In the above-mentioned article in Table 1 a bullet point in the rectum column for Salofalk Granu-Stix was included and “pH-dependent plus additional enzymatic activation (non-pH-dependent)” in the pH release profile column for Asacol 1600 mg modified-release tablets was added ([ Table 1 ]). Table 1 Drug-release profiles and kinetics of different mesalazine formulations (alphabetical order). Site of release Commercial product pH release profile duodenum jejunum ileum ascending colon transverse colon descending colon sigmoid colon rectum Asacol enteric-coated tablets (0.4 g, 0.8 g) [75, 76] pH-dependent • • • • • Asacol modified-release tablets (1.6 g) [77] pH-dependent plus additional enzymatic activation (non-pH-dependent) • • • • • Claversal micro-pellets (enteric-coated granules) (1.5 g) [78] pH-dependent • • • • • Claversal enteric-coated tablets (0.5 g) [79] pH-dependent • • • • • Mezavant enteric-coated, prolonged-release tablets (1.2 g) [80] pH-dependent • • • • • Pentasa prolonged-release granules (1 g, 2 g, 4 g) [81] Time-dependent (not pH-dependent) • • • • • • • • Pentasa prolonged-release tablets (0.5 g, 1 g) [81, 82] Time-dependent (not pH-dependent) • • • • • • • • Salofalk Granu-Stix (prolonged-release granules) [83] (0.5 g, 1 g, 1.5 g, 3 g) [83] pH-dependent • • • • • • Salofalk enteric-coated tablets (0.25 g, 0.5 g, 1 g) [84, 85, 86] pH-dependent • • • • • Additionally in reference number 79 the link to the "Fachinformation (SmPC) Claversal 500 mg magensaftresistente Tabletten” was changed. The correct link in this case is as follows: https://www.fachinfo.de/fi/detail/021892/claversal-r-500-mg-tabletten?query=claversal%20500 . This was corrected in the online version on March 13th, 2026. Publication History Article published online: 13 March 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

Autor:innen und Institutionen

  • Internal Medicine III, University Hospital Augsburg, Augsburg, Germany.
  • Department of Medicine I, Goethe-University, Agaplesion Markus Hospital, Frankfurt, Germany.
  • Independent public health researcher, Madrid, Spain.
  • Department of Gastroenterology, Lüneburg Hospital, Lüneburg, Germany.

Zitieren

APA

Schnoy, E., Dignass, A., Gaskins, M., & Kucharzik, T. (2025). Correction: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis. Zeitschrift für Gastroenterologie, 63(10), e668-e669. https://doi.org/10.1055/a-2832-4215

Vancouver

Schnoy E, Dignass A, Gaskins M, Kucharzik T. Correction: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis. Zeitschrift für Gastroenterologie. 2025;63(10):e668-e669. doi:10.1055/a-2832-4215

BibTeX
@article{Schnoy2025,
  author = {Schnoy, Elisabeth and Dignass, Axel and Gaskins, Matthew and Kucharzik, Torsten},
  title = {Correction: From guidelines to evidence-based practice – A German perspective on mesalazine as first-line therapy for mild-to-moderate ulcerative colitis},
  journal = {Zeitschrift für Gastroenterologie},
  year = {2025},
  volume = {63},
  number = {10},
  pages = {e668--e669},
  doi = {10.1055/a-2832-4215}
}
Kostenlos starten →